Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
118.64 USD | +0.30% | +3.43% | +8.82% |
09-18 | Merck Secures FDA Approval for Keytruda Combination Therapy as Malignant Pleural Mesothelioma Treatment | MT |
09-18 | Merck Gets First FDA Approval of Keytruda in Malignant Pleural Mesothelioma | DJ |
Cet article est réservé aux membres
Déjà membre ?
Log InNot a member ?
Free registration- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- UBS Adjusts Merck & Co.'s Price Target to $142 From $148, Maintains Buy Rating